Ugly reversal for Inovio

|About: Inovio Pharmaceuticals... (INO)|By:, SA News Editor

After being up as much as13% in today's session, Inovio (INO -14.2%) turns tail and plummets 24% from its intraday high of $12.20 on a 10x surge in volume. On a purely technical basis, the intensity of the bearish reversal should put longs on high alert.

Earlier today the company announced the initiation of a Phase 1/2a clinical trial to evaluate the safety, immunogenicity and clinical responses of INO-3112, a combination immunotherapeutic candidate for HPV-associated head and neck cancer.